ONCY(ONCY)
ONCY
Key MetricsTTM
Market Cap$111.71M
Revenue TTM$0.00
Net Income TTM-$31.32M
Free Cash Flow-$28.56M
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity4596.7%
Return on Assets-383.7%
Debt / Equity-0.10
Current Ratio1.38
EPS TTM$-0.28
PRICE
Prev Close
0.79
Open
0.81
Day Range0.79 – 0.82
0.79
0.82
52W Range0.33 – 1.51
0.33
1.51
40% of range
VOLUME & SIZE
Avg Volume
1.1M
FUNDAMENTALS
P/E Ratio
-2.5x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
0.89
Market-like
TECHNICAL
RSI (14)
39
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 116 days
Sep 15
ONCY News
About
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning 'cold' tumors 'hot' -- through innate and adaptive immune responses to treat a variety of cancers.
Industry
Research and Development in Biotechnology
Website
Andrew AromandoChief Business Officer
Allison HagermanChief Technology Officer
Yujun WuVP & Head of Biostatistics
Jon PattonDirector of Investor Relations & Communication
John Mark LievonenConsultant
John McAdoryExecutive VP of Strategy & Operations
Jared KellyChief Executive Officer & Director
Kirk J. LookChief Financial Officer
Thomas C. HeinemanChief Medical Officer